Completed PHASE1 INTERVENTIONAL 1-arm NCT01527838

Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

A Phase I Trial of a Single FT1050 (16,16-Dimethyl Prostaglandin E2) Ex Vivo-Modulated Umbilical Cord Blood (CB) Unit Following a Reduced Intensity Conditioning Regimen For Adults With Hematologic Malignancies

Sponsor: Fate Therapeutics

Conditions Acute Lymphoblastic Leukemia (ALL) Acute Myelogenous Leukemia (AML) Chronic Lymphocytic Leukemia (CLL) Hodgkin's Disease Non-Hodgkin's Lymphoma (NHL)

Interventions Single FT1050 treated UCB unit

Updated 6 times since 2017 Last updated: Sep 9, 2016 Started: Jan 31, 2012 Primary completion: Oct 31, 2013 Completion: Nov 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Acute Lymphoblastic Leukemia (ALL) and Acute Myelogenous Leukemia (AML), this trial is completed. The trial is conducted by Fate Therapeutics and has accumulated 6 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fate Therapeutics

Data source: Fate Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Columbus, United States